US20080241191A1 - Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies - Google Patents

Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies Download PDF

Info

Publication number
US20080241191A1
US20080241191A1 US11/982,410 US98241007A US2008241191A1 US 20080241191 A1 US20080241191 A1 US 20080241191A1 US 98241007 A US98241007 A US 98241007A US 2008241191 A1 US2008241191 A1 US 2008241191A1
Authority
US
United States
Prior art keywords
pneumoniae
antigen
polysaccharide antigen
streptococcus pneumoniae
cell wall
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/982,410
Inventor
Norman James Moore
Mary Kathleen Fent
Vladimir Andrei Koulchin
Elena Valentin Molokova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alere Scarborough Inc
Original Assignee
Alere Scarborough Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US15648698A priority Critical
Priority to US09/397,110 priority patent/US6824997B1/en
Priority to US10/989,050 priority patent/US20050148039A1/en
Priority to US11/740,738 priority patent/US20070265433A1/en
Application filed by Alere Scarborough Inc filed Critical Alere Scarborough Inc
Priority to US11/982,410 priority patent/US20080241191A1/en
Publication of US20080241191A1 publication Critical patent/US20080241191A1/en
Assigned to GENERAL ELECTRIC CAPITAL CORPORATION reassignment GENERAL ELECTRIC CAPITAL CORPORATION SECURITY AGREEMENT Assignors: ADVANTAGE DIAGNOSTICS CORPORATION, ALERE MEDICAL INCORPORATED, ALERE SAN DIEGO, INC., ALERE SCARBOROUGH, INC., AMEDITECH INC., APPLIED BIOTECH, INC., BINAX, INC., BIOSITE INCORPORATED, CHOLESTECH CORPORATION, GENECARE MEDICAL GENETICS CENTER, INC., HEMOSENSE, INC., INSTANT TECHNOLOGIES, INC., INVERNESS MEDICAL - BIOSTAR INC., ISCHEMIA TECHNOLOGIES, INC., MARTIA HEALTHCARE, INC., MATRITECH, INC., ZYCARE INC.
Assigned to BINAX, INC. reassignment BINAX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FENT, MARY KATHLEEN, MOORE, NORMAN JAMES, KOULCHIN, VLADIMIR ANDREI, MOLOKOVA, ELENA VALENTIN
Assigned to ALERE SCARBOROUGH, INC. reassignment ALERE SCARBOROUGH, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BINAX, INC.
Assigned to INSTANT TECHNOLOGIES, INC., BINAX, INC., AMEDITECH INC., ISCHEMIA TECHNOLOGIES, INC., CHOLESTECH CORPORATION, HEMOSENSE, INC., ALERE SAN DIEGO, INC., ALERE SCARBOROUGH, INC., ZYCARE, INC., APPLIED BIOTECH, INC., ADVANTAGE DIAGNOSTICS CORPORATION, MATRITECH, INC., BIOSITE INCORPORATED, INVERNESS MEDICAL - BIOSTAR INC., GENECARE MEDICAL GENETICS CENTER, INC., ALERE MEDICAL, INC., MATRIA HEALTHCARE, INC. reassignment INSTANT TECHNOLOGIES, INC. NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287 Assignors: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Assigned to GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT reassignment GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT INTELLECTUAL PROPERTY SECURITY AGREEMENT Assignors: ALERE CONNECT, LLC, ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.), ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.), ESCREEN, INC., INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.), IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.), QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.), STANDING STONE, LLC
Assigned to HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT reassignment HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Assignors: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
Assigned to ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.), INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.), IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.), ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.), QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.), ESCREEN, INC., ALERE CONNECT, LLC, STANDING STONE, LLC reassignment ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.) RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Assignors: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56944Streptococcus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/78Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N2021/752Devices comprising reaction zones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N2021/757Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated using immobilised reagents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N2021/7756Sensor type
    • G01N2021/7759Dipstick; Test strip
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
    • G01N2333/3156Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/10Detection of antigens from microorganism in sample from host

Abstract

Disclosed is a cell wall C-polysaccharide antigen of Streptococcus pneumoniae which contains not more than 10% by weight of protein, and preferably less which has been purified with 0.1N NaOH prior to deproteinizing. Also disclosed are polyvalent antibodies raised against Streptococcus pneumoniae which have been affinity purified by passing them over a chromatographic affinity matrix to which is coupled the purified and at least partially deproteinized antigen to render them antigen-specific.

Description

    PARENT APPLICATION
  • This application is a division of U.S. application Ser. No. 09/397,110 filed Sep. 16, 1999, which is in turn a continuation in part of U.S. application Ser. No. 09/156,486 filed Sep. 18, 1998 in the names of the same inventors.
  • BRIEF DESCRIPTION OF THE INVENTION
  • The present invention relates to a purified carbohydrate antigen of S. pneumoniae and its use in affinity purifying antibodies raised in an animal against S. pneumoniae bacteria or against the carbohydrate antigen. The affinity purified antibodies are especially useful in a specific and sensitive immunochromatographic (“ICT”) assay, performable within about 15 minutes, for the detection of Streptococcus pneumoniae in a bodily fluid, such as urine or cerebrospinal fluid, of a patient showing clinical signs of an infection caused by S. pneumoniae.
  • BACKGROUND OF THE INVENTION
  • Streptococcus pneumoniae (“S. pneumoniae”) is a leading causative organism of pneumonia-type illnesses and other lower respiratory tract infections such as bronchitis, as well as of upper respiratory tract infections, including infectious otitis media and sinusitis and of disseminated invasive infections, including bacteremia and meningitis. When not properly diagnosed and treated, S. pneumoniae pneumonic infection may lead to any of pericarditis, empyema, purpura fulminans, endocarditis or at least one type of arthritis, where S. pneumoniae is the causative organism in each instance. Such pneumonic infection is also often a precursor of bacteremia or meningitis. To now, it nevertheless is common for pneumonia arising from S. pneumoniae to be diagnosed and treated somewhat empirically.
  • To a significant extent, this is because the tests presently available for the detection of S. pneumoniae are either (1) time consuming, labor intensive and in need of instrumental assistance for reading results, or (2) lacking in sensitivity and/or specificity. Because of problems associated with lack of sensitivity and/or specificity, e.g., physicians tend toward conservatively prescribing expensive, broad spectrum antibiotics for patients with pneumonia-type respiratory infections in lieu of prescribing a less expensive antibiotic specific to S. pneumoniae where it would adequately cure the infection. This and other liberal prescribing of broad spectrum antibiotics is, of course, a major cause of today's well-publicized medical crisis consequent from the increasing resistance of many types of infectious bacteria to previously highly efficacious antibiotics. This crisis and the potential untoward consequences for at least some patients of empirical diagnosis and treatment are among many reasons why a reliable and rapid assay for detecting S. pneumoniae in human body fluids is needed.
  • Pneumonia caused by S. pneumoniae is a serious disease, estimated to occur at the rate of one to five cases per 1,000 persons per year in the United States alone. Depending upon the age and state of health (based on unrelated factors) of patients infected with S. pneumoniae-caused pneumonia, the disease has a mortality rate of between 4 percent and 30 percent of infected patients.
  • The most time-honored methods of attempting to diagnose S. pneumoniae-caused diseases, and especially pneumonia, involve the Gram stain and culture of expectorated sputum of patients suspected of harboring the disease, followed by biochemical identification methods. This procedure requires in the order of one to four days from start to finish. It has proved to be an unsatisfactory diagnostic tool because (1) other bacteria present in the patient's saliva often overgrow the sputum culture, and (2) S. pneumoniae frequently is present in the human upper respiratory tract even when no sign of disease attributable to this bacterium is present in the individual. For example, it is estimated that some 30 percent of U.S. children are habitual carriers of S. pneumoniae. Adults, too may become colonized by S. pneumoniae without themselves entering a disease state. The carriage rates of the organism by both children and adults increase with crowding conditions and during winter months.
  • Co-agglutination, latex particle agglutination and counter-immunoelectrophoresis methods for detecting the polysaccharide capsular antigens of S. pneumoniae in sputum specimens have been developed and are rapid, but they have not been shown to exhibit reliable sensitivity or specificity, probably because there are some 83 serotypes of S. pneumoniae, each of which may vary in immunogenicity and in other respects. The commercial polyvalent anti-serum developed and used for these tests contains antibodies to all 83 of the S. pneumoniae serotype antigens, but it nevertheless may fail to detect the less immunogenic antigen serotypes. This polyvalent antiserum also has shown cross-reactivity with other streptococci and some other infectious bacteria, e.g., Haemophilus influenzae. Hence both false-negative and false-positive reactions may occur randomly when these tests are used on sputum samples.
  • Several enzyme-immunoassays (“EIA”) have been developed which are based on detection of the pneumococcal C-polysaccharide antigen that has been found to be present in the pneumococcal cell wall of all of the S. pneumoniae serotypes. See, e.g., Parkinson, A. J., Rabiego, M. E., Sepulveda, C., Davidson, M. and Johnson, C., 30 J. Clin. Microbiol. 318-322 (1992). This C-polysaccharide antigen is a phosphocholine-containing polysaccharide derived from teichoic acid. These EIA assays are of acceptable specificity and sensitivity even though most often performed on sputum samples. Each such assay, however, requires two to three hours performance time after sample collection as well as the use of instrumentation normally available primarily in clinical laboratories. In addition, these assays need to be run by, or under close supervision of, trained personnel.
  • Reliance upon sputum samples to diagnose S. pneumoniae infections is frequently less than satisfactory in achieving a diagnosis of S. pneumoniae-caused pneumonia, and not just because of the potential for contamination of the sample by other bacteria in the mouth and/or by indigenous upper respiratory tract S. pneumoniae. Sputum is often difficult to collect; more-over, once medication of the patient is commenced, the number of viable S. pneumoniae in sputum rapidly decreases. In particular, the presence of the C-polysaccharide antigen in sputum may rapidly become difficult to detect if an antibiotic therapy is used that attacks the cell wall of the S. pneumoniae microorganism. When S. pneumoniae causes infectious otitis media, meningitis and various other aforementioned infectious disease states, sputum samples are of no aid in diagnosis.
  • Collection of blood cultures from patients suspected of S. pneumoniae infection eliminates the contamination problems that attend sputum samples. Where blood serum samples are found to contain S. pneumoniae, diagnosis of various diseases of which it is causative may readily be made. The drawback here is that only about 20 percent of all pneumonia patients infected by S. pneumoniae become bacteremic; therefore, relying solely on blood samples to diagnose S. pneumoniae-caused pneumonia may yield false-negative results.
  • Urine samples have been found to be the most reliable and convenient ones to use in detecting S. pneumoniae-caused pneumonia because they can be non-invasively obtained; they will not be contaminated with oral microflora; and the presence of the bacterium in urine persists, albeit at a constantly decreasing level of concentration, even after patient therapy has been initiated, so that daily monitoring of patient urine samples to assess the efficacy of a prescribed therapy may yield useful information. It should be noted that human carriers of S. pneumoniae who show no disease symptoms often do not have sufficient pathogen present to have S. pneumoniae antigens present in their urine.
  • A very recent article describes the successful diagnosis of meningitis caused by S. pneumoniae using an EIA method to test samples of cerebrospinal fluid. In the EIA, a monoclonal immunoglobulin A antiphosphoryl-choline antibody was employed to detect the C-polysaccharide antigen. See Stuertz, K, Merx, I, Eiffert, H., Schmutzhard, E., Mader, M. and Nau, R., 36 J. Clin. Microbiol. 2346-2348. The results obtained compared favorably with those reported by Yolken, R. H., Davis, D., Winkelstein, J., Russell, H. and Sippel, J. E., 20 J. Clin. Microbiol. 802-805 (1984) obtained in an EIA in which two antibodies for S. pneumoniae in cerebrospinal fluid were used—a horse antibody to the pneumococcal C-polysaccharide antigen, bound to microtiter plates, and a pooled rabbit antiserum to the polysaccharide capsular antigen in the liquid phase.
  • BRIEF DESCRIPTION OF THE INVENTION
  • According to the present invention, antibodies to the C-polysaccharide antigen of S. pneumoniae raised in rabbits are affinity purified with isolated and purified C-polysaccharide antigen having less than about 10% protein content.
  • These affinity purified antibodies are conjugated to an agent which produces a color reaction upon the formation of a sandwich with S. pneumoniae C-polysaccharide antigen from a test sample and additional affinity purified C-polysaccharide antibody immobilized upon a nitrocellulose matrix.
  • The test is conducted in a disposable immunochromatographic test device and requires no instrumentation to interpret the result. It can easily and successfully be performed by persons who have no training in laboratory techniques.
  • The preferred test sample for diagnosis of S. pneumoniae-caused pneumonia is patient urine, but the test also works with other bodily fluid samples that contain S. pneumoniae, including serum and sputum. Diagnosis of S. pneumoniae-caused meningitis may be readily made using patient cerebrospinal fluid as the test sample.
  • This invention for the first time offers the benefit of a test for S. pneumoniae that is performable within a 15-minute time span and is of at least equal specificity and sensitivity to EIA tests requiring eight to twelve times as long and much more work, to obtain a result. The test is easy to perform, requires no special training, equipment, or instrumentation and it enables a rapid diagnosis of pneumonia caused by S. pneumoniae. It can be readily performed in a doctor's office, thus permitting the patient to be immediately placed on a S. pneumoniae-specific therapeutic regimen. It can, of course, be performed in a clinical laboratory, but it can also easily be performed in a geriatric center, in a patient's home or in any environment where S. pneumoniae-caused pneumonia or other pathogenic condition is suspected to be epidemic.
  • The test of this invention is important to administer when disease states such as otitis media, bronchitis or sinusitis appear because once it can be established that any of these is due to S. pneumoniae rather than another infectious agent, appropriate therapy can promptly be initiated. Small children are especially prone to otitis media because of the shorter length and smaller diameter of their Eustachian tubes, so that early detection of S. pneumoniae if present may well forestall the onset of a more serious, or even life-threatening, disease state. Papers by Norris et al, J. Pediatrics, 821-827 (1966) and Hongeng et al, 130 J. Pediatrics, No. 5 (May 1997) indicate that children with sickle cell disease are highly susceptible to S. pneumoniae infection, with S. pneumoniae sepsis being the most common invasive infection among this populace and those once so infected having a much heightened risk of recurrence and subsequent death. Clearly, employing the ICT test of this invention to test the urine of these patients on a regular basis may be helpful in diminishing the need for the unremitting penicillin prophylaxis that the second of these papers recommends.
  • The ease of performance of the test and its ability to detect the C-polysaccharide antigen of S. pneumoniae in urine suggests that this test should prudently be performed on patients without overt clinical signs of related infection who report feeling substantially under par. Any such patient in whom it is established that S. pneumoniae is present in significant enough quantities to give a positive urine ICT test is a predictable candidate for developing a more severe infection—and the ability to forestall the disease development before it becomes severe by administering appropriate therapy is newly presented by this invention.
  • As a part of developing the rapid test of this invention, applicants have also developed a novel purified form of the C-polysaccharide cell wall antigen that is indigenous to all serotypes of S. pneumoniae. This novel purified antigen is of special use in affinity purifying polyvalent antibodies raised in an animal against S. pneumoniae bacteria or against the crude C-polysaccheride antigen.
  • DESCRIPTION OF THE DRAWINGS
  • FIG. 1 and related FIGS. 1A, 1B and 1C hereof show the structure of a typical ICT device which has been adapted to perform the S. pneumoniae assay as hereinafter described in detail.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Broadly speaking, the ICT assay for S. pneumoniae as herein described may be designed and configured to be run on any known disposable ICT device disclosed in the art. Preferably it is designed to be conducted, and is conducted, using an ICT device of the type disclosed in copending U.S. patent Application Serial No. now U.S. Pat. No. 6,168,956 Ser. No. 07/706,639, of Howard Chandler, or one of its continuation-in-part applications, all of which are assigned to Smith-Kline Diagnostics, Inc. but are exclusively licensed to Binax, Inc. (which is entitled to assignment of this application), in a wide area of use fields that includes diagnoses of human respiratory system diseases.
  • The preferred device is suitably impregnated in one region thereof with antigen-specific polyvalent antibodies to the C-polysaccharide antigen of S. pneumoniae. Labeled antigen-specific antibodies are applied to another area of the device. The test sample suspected of containing S. pneumoniae is contacted first with the labeled antigen-specific antibodies, which then flow with the sample to the device area containing unlabeled bound antigen-specific antibodies, whereupon if S. pneumoniae is present in the sample, the labeled antibody:C-polysaccharide antigen conjugate already formed by contact binds to the immobilized unlabeled affinity purified antibodies, whereupon a visible color reaction is produced. The label may be any substance known in the art to produce visible color upon the reaction of a labeled antibody:antigen complex with bound unlabeled antibodies. Such labels include various finely divided metallics, various organic molecules, and various molecular combinations such as enzyme combinations with another color-producing molecule. In this invention, colloidal gold particles constitute the preferred label.
  • It is of major importance in designing the test device, that the concentration of antibody present at each of the two sites of the test device where reaction occurs be sufficient to insure that antigen present in the test sample will be captured by the labelled antibodies as the test sample contacts them and that labelled antibody: antigen conjugate will be readily captured and held by the bound antibodies at the sample capture line. Experimental work undertaken in connection with this invention has shown that active antibody to the C-polysaccharide antigen of S. pneumoniae must be present at each site of a test device at which antigen: antibody reaction is to occur, in a concentration of between 7.7 nanograms/sq. mm. of surface area and 385 nanograms/sq. mm. of surface area. If antibody concentrations lower than 7.7 nanograms/sq. mm. are present at a site where reaction is intended to occur, false negative results are likely.
  • Various methods of affinity purification of antibodies to the C-polysaccharide antigen of S. pneumoniae, are known. The one hereinafter described is preferred in the present invention, but others may be substituted. It is noted, however, that the affinity-purified antibodies of this invention are to be sharply distinguished from the “affinity-purified antibody preparation” which is described by Sjogren and Holme, 102 J. Immunol. Methods 93-100 (1987). These authors describe obtaining a hot phenol-purified C-polysaccharide antigen of S. pneumoniae containing 17% protein and absorbing it on an ion exchange gel, DE AE—Sepharose CL6B. After 48 hours incubation this preparation was packed into columns at approximately neutral pH of 7.2. The binding efficiency of the antigen to the gel is said to be about 60%. Antibodies were passed over these columns and incubated for 30 minutes, followed by elution of the columns with 0.5 M Na Cl in PBS. It is known that leakage of antigen from ion-exchange columns is a frequent occurrence. In this system, it is reasonable to hypothesize that the product eluted from the gel was an in situ-formed immune complex of antibodies and antigen rather than a preparation of the purified antigen of this invention. It should particularly be noted that, in this invention, the purified antigen containing less than 10% protein is covalently coupled to a spacer molecule such as BSA—hydrazine conjugate, and the resulting labile antigen-conjugate ligand is then covalently coupled to a chromatographic gel—e.g., the Formyl Spherilose of Example 4, which is then applied to a column. The antibodies are added and eluted, with strongly acidic buffer, from the immobilized antigen on the column.
  • The antibody herein preferred is raised by conventionally injecting a rabbit with S. pneumoniae strain R6, a non-encapsulated S. pneumoniae strain available from the American Type Culture Collection under ATCC No. 39938 which is subjected to heat-killing of the cells before injection into the animal. After an appropriate time period, the animal is bled to obtain serum containing the desired antibodies, followed by purification thereof. Other antibodies to the S. pneumoniae C-polysaccharide antigen may be substituted for those specifically described herein without departing from this invention.
  • The antibody should initially be tested for cross reactivity to other common infectious bacteria. The preferred antibody referred to herein was tested, using the ELISA method, for cross-reactivity with each of the following: Citrobacter freundii, Staphylococcus aureus, Enterobacter cloacae, Enterobacter faecalis, Streptococcus Group B Type III, E. coli, Neisseria meningitidis, Salmonella cubana, Salmonella paratyphi A, Klebsiella pneumoniae, Streptococcus Group B type II, Staphylococcus epidermidis, Salmonella enteritidis, Streptococcus Group A, Serratia marcescens, Candida albicans, Haemophilus influenzae, Moraxella catarrhalis, Corynebacterium kutscheri, Pseudomonas putida, Proteus vulgaris, Enterococcus avium, Acinetobacter baumannii, Klebsiella oxytoca, Acinetobacter lwoffli, Pseudomonas aeroginosa, Staphylococcus saphrophyticus, Enterococcus durans, Corynebacterium bovis, Proteus mirabilis, Pseudomonas stutzeri, Pseudomonas cepacia, Salmonella typhi, Streptococcus Group F, Streptococcus Group B type 1a, Candida stellatoides, Streptococcus parasanguis, Streptococcus Group G, Streptococcus Group C, Streptococcus mutans, Morganella morganii, Staphylococcus haemolyticus, Haemophilus influenzae type B, Stenotrophomonas maltophilia, Haemophilus influenzae type D, Gardnerella vaginalis, Streptococcus mitis, Haemophilus parainfluenzae, Streptococcus sanguis, and H. influenzae nontypeable.
  • The only significant cross reactivity found was with Streptococcus mitis and Staphylococcus aureus. The first, S. mitis, is a causative agent for endocarditis, the overt patient symptoms of which physicians can readily distinguish clinically from those of an S. pneumoniae lung infection. S. mitis contains the same C-polysaccharide antigen as S. pneumoniae and the two share the ability to cause endocarditis, albeit S. pneumoniae normally does so in patients whose primary pneumonia has not been appropriately treated and who may then develop bacteremia and/or endocarditis or another pathogenic secondary infection. S. mitis, by contrast, is not a causative agent for pneumonia; endocarditis attributable to S. mitis normally develops independently of any other infection. It is accordingly believed that suspected cases of primary endocarditis caused by S. mitis can be confirmed, when needed, using the assay of this invention. It should be noted, however, that S. mitis is less likely to be present in urine than S. pneumoniae and hence, an assay of blood serum may be more likely to yield confirmatory information in that instance.
  • Some strains of S. aureus are known to secrete Protein A, a non-specific protein which indiscriminately binds IgG, and hence, all antibodies. The suspected presence of these S. aureus entities may be readily confirmed or ruled out by running other simple tests well known in the art. (As shown in Example 9, S. aureus strains in which protein A is not present show no cross reactivity to the antibody of this invention.) A minor cross-reaction with Haemophilus influenzae was observed, but is not believed to be significant enough to cause a problem in the detection of S. pneumoniae in urine samples.
  • The following examples illustrate the preferred mode of affinity purification of the antibody, including the preliminary separation and purification of the antigen used to effect antibody purification, thus yielding an antigen-specific polyvalent antibody preparation.
  • EXAMPLE #1 Bacterial Growth Conditions
  • S. pneumoniae strain R6 (ATCC No. 39938) was grown in S. pneumoniae broth supplemented with 20 mM of Hepes buffer. The broth had the following composition per liter:
  • Pancreatic digest of casein 17.0 g.
    Glucose 10.0 g.
    NaCl 5.0 g.
    Papain digest of soybean meal 3.0 g.
    Yeast extract 3.0 g.
    K2 HPO4 2.5 g.
    HEPES 20 mM

    This broth had an initial pH of 7.2±0.2 at 26° C. It was autoclaved for 15 minutes at 15 psi and 121° C. and set aside to cool.
  • Frozen aliquots of S. pneumoniae strain R6 (ATCC No. 39938) were inoculated onto 5% sheep blood agar plates and allowed to grow. Growth from the plates was harvested in smaller aliquots of the seed broth and this seed broth was inoculated into three flasks, each containing 1,700 ml of supplemented S. pneumoniae broth of the composition shown above and further grown at 37° C. in an atmosphere of 5 percent CO2, with agitation but not aeration. When the pH of the broth fell below 5.5 (its late log phase) the flasks were removed from the incubator, the cells were killed with 0.1 percent sodium azide and the pH was adjusted to above 7.0 to prevent autolysis. The flasks were then stored at 4° C. overnight. The following day, the suspension from each flask was centrifuged at 8,000 rpm for 60 minutes. The pellets were then combined and recentrifuged at 13,000 rpm for 30 minutes. The wet weight of the pellet was recorded and it was stored at −20° C.
  • EXAMPLE #2 Isolation of S. pneumoniae C-Polysaccharide Antigen Containing Less than 10% Protein
  • Cells grown, treated and stored as in Example 1 were thawed at room temperature and suspended in phosphate-buffered saline solution (“PBS”) of pH 7.2 with 0.2 percent of sodium azide in a ratio of 1.2 ml. of buffer to 1 gram of wet cells and left at room temperature for two days.
  • Eleven ml per gram of the wet cells of 0.1 N NaOH was then added to the S. pneumoniae suspension (in phosphate buffered saline), resulting in a pH of 12.34 (as measured by pH meter) and incubated for 45 minutes at about 30° C. The pH of the suspension was then adjusted to 2.75 (measured by pH meter) with 2 N HCl, followed by centrifuging the suspension at 3,500 rpm for 25 minutes. The supernatant was then separated and its pH was adjusted to 7.0-7.1 with 1 N NaOH. This essentially neutralized supernatant was dialyzed at 4° C. against water for two days in dialysis tubing (obtained from Spectra/Por) having a molecular weight cut-off of 12,000 to 14,000. The dialyzed supernatant was concentrated 25 to 40 times on a vacuum rotary evaporator.
  • Proteinase K (from Boehringer Mannheim) in the amount of 0.20 mg. per gram of wet cells, was added and the mixture was allowed to stand at 37° C. for three and one-half to four hours and then at room temperature overnight and the next day.
  • Following digestion with Proteinase K, the resulting supernatant was dialyzed at 4° C. against water in the dialysis tubing from Spectra/Por having a molecular weight cut-off of 12,000-14,000. The dialyzed supernatant was thereupon divided into 12 aliquots, each of which was placed in a 30 ml glass tube and mixed with an equal volume of 90 percent phenol. The tubes were closed and incubated for 23 minutes at 68-72° C. in a thermal water bath wherein the water level was slightly above that of the mixture level in the tubes. The suspension in each of the tubes was occasionally stirred with a glass Pasteur pipette to make the suspension more nearly homogeneous to the naked eye. After this incubation, the suspension was allowed to stand at room temperature for 30 minutes and then was centrifuged at 5,000 rpm for 40 minutes at a temperature of 15° C.
  • The upper water phase in each tube was then carefully withdrawn with a glass syringe; its volume was carefully measured for each individual tube and it was replaced with an equal volume of fresh water. The steps of incubation of the suspension at 68-72° C. followed by centrifugation at 5,000 rpm for 40 minutes at 15° C., was performed again and repeated then repeated once.
  • The lower phenol phase in each of the tubes was then carefully withdrawn with a glass syringe, leaving the intermediate (mixed water-phenol) and upper (water) phases in the tubes.
  • Meanwhile a flask containing cold ethanol, in a volume ratio of about 10:1 relative to the combined extracted phenol phase from the tubes, was placed in an ice bath. To this flask the phenol phase was slowly added, drop by drop, with intensive stirring. After all of the phenol phase was added, stirring was continued for 10 to 15 minutes, whereupon the mixture was placed in a refrigerator at 4° C. and left overnight to foster pelleting of the C-polysaccharide antigen. The following day the mixture was subjected to centrifugation at 12,000 rpm for 20 minutes at 4° C. The resulting pellet of C-polysaccharide antigen was suspended in about 0.4 ml per gram of wet cells of water and dialyzed against distilled water at 4° C. overnight, using the Spectra/Por tubing with molecular weight cut-off of 12,000-14,000 referred to above. The resulting aqueous solution of C-polysaccharide antigen was lyophilized and weighed. Its protein concentration was evaluated by the Lowry Method; its composition was checked on SDS-PAGE (12 percent gel) by Western immunoblot assay and its C-polysaccharide antigen activity was checked by ELISA.
  • This operation was repeated a number of times. It was found that the overall yield of S. pneumoniae C-polysaccharide antigen was from 1.2 to 1.4 percent per gram of wet cells of S. pneumoniae strain R6, while its protein content was between about 5 and about 8 percent.
  • It should be noted that, in general, C-polysaccharide antigen preparations with a protein content exceeding 10% are less likely to perform satisfactorily in this invention than preparations of less than 10% protein content.
  • EXAMPLE #3 Preparation of BSA Conjugate of the Antigen
  • For coupling of the purified S. pneumoniae strain R6 C-polysaccharide antigen to a chromatographic column to permit affinity purification of rabbit anti-S. pneumoniae strain R6 antibodies, a BSA-hydrazine conjugate was selected. Other known materials having similar functions may be selected and conjugated to accomplish this coupling function.
  • The BSA-hydrazine conjugate was prepared as follows:
  • Hydrazine dihydrochloride obtained from Aldrich Chemical Co. was dissolved in water to produce an 0.5 M solution. The pH was adjusted to 5.2 with dry NaOH and dry bovine serum albumin (“BSA”) from Sigma Chemical Co. was added to produce a final concentration of BSA of 25 mg per ml of solution. After complete dissolution of BSA, N-(dimethylamino-propyl)-N1-ethylcarbodiimide hydrochloride (from Fluka Chemical Co.) was added in a quantity to produce a final concentration of 2.5 mg per ml of solution. This reaction mixture was incubated at room temperature, with continuous stirring, overnight. The next day, it was intensively dialyzed against distilled water at 4° C. Concentration of conjugate was measured (as BSA concentration) at 280 nm on a Beckman DU 640 spectrophotometer.
  • To couple this conjugate to S. pneumoniae strain R6 C-polysaccharide antigen, the procedure was as follows:
  • The dry preparation of the antigen was dissolved, in the amount of 1.1 mg per ml, in distilled water. Using diluted HCl, the solution pH was adjusted to 5.0-6.0. BSA:hydrazine conjugate in aqueous solution in a concentration of 23 mg per ml was treated with dilute HCl to bring its pH to between 4.0 and 5.0, and this solution was then slowly added to the antigen solution in a volume ratio of about 1:6.65 (about 3:1 by weight). After three minutes of stirring, N-(dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (from Fluka Chemical Co.) in about 100 to 200 mcl of distilled water was added to the reaction mixture in a N-ethylcarbodiimide hydrochloride to C-polysaccharide antigen weight ratio of about 1 to 1.92.
  • After stirring for two hours at room temperature, the pH of the resulting mixture was adjusted to about 9.0 with dilute NaOH. The incubation was thereupon continued at room temperature for one hour and then at 4° C. overnight.
  • EXAMPLE #4 Affinity Column Preparation and Antibody Purification
  • To the ligand solution from Example 3, dilute HCl was added to bring its pH to 7.0. Formyl Spherilose from Isco, Inc. was selected as the matrix for the immunoadsorbent gel. The ligand of C-polysaccharide antigen was coupled to this matrix using known procedures, e.g., as described in Spherilose applications, ISCO Applications Bulletin 78 at pages 28-35. Other known matrices and coupling procedures may be substituted.
  • The gel was packed into the column and washed alternatively with distilled water, 0.2 M glycine-HCL solution of pH 2.5, triple strength phosphate-buffered saline of pH 7.2 and regular strength PBS of pH 7.2, using 5 to 10 volumes per volume of the gel of each solution.
  • The resulting activated column was then used for affinity purification of antibodies, thus producing antigen-specific antibodies, as follows:
  • Rabbit antiserum to S. pneumoniae Strain R6 (ATCC No. 39938) directed to whole heat-killed cells, was mixed with dry NaCl to a final concentration of 0.5 M. This mixture was centrifuged at 8,500 rpm for 20 minutes and the supernatant was filtered through cotton wool. The filtrate was applied on the affinity column. The unbound components were washed from the column with triple strength phosphate buffered saline of pH 7.2 and with regular strength phosphate buffered saline of pH 7.2. The antibodies were eluted from the column with 0.2 M glycine-HCl buffer of pH 2.5. The eluent was monitored at 280 nm on the Beckman spectrophotometer and the fractions containing antibodies were pooled in a flask which was placed in an icewater bath. The pooled fractions were neutralized with aqueous 0.5 M NaH2PO4 of pH 9.0.
  • The concentration of antibodies was evaluated from the absorbance value at 280 nm on the spectrophotometer.
  • The antibody solution was dialyzed against PBS of pH 7.2 and concentrated on a PM-10 filter obtained from Amicon until a concentration of 0.8-1.5 mg/ml of antibody was achieved.
  • It was found that 18-20 mg of affinity purified antibodies were recovered from each 25 ml of rabbit antiserum to S. pneumoniae strain R6 so treated.
  • These affinity purified antibodies were utilized in an ICT test specific for S. pneumoniae C-polysaccharide antigen as described in the ensuing example.
  • EXAMPLE #5 ICT Device and its Preparation
  • A. Preparation of Test Device:
  • A test device comprising a hinged cardboard housing equipped with a window to allow the viewing of both the test results and control results was prepared as shown in FIG. 1. The device has a recess into which is placed a preformed plastic swab well for receiving the sample-wetted swab on the right-hand (labeled 1 in the drawing). An overlabel shown in FIG. 1A is then placed over the entire right-hand side of the device. The overlabel has been equipped with two holes—a lower one (marked B on FIG. 1A) into which the saturated swab is to be inserted and an upper one (marked B on FIG. 1A) toward which the swab will be pushed after insertion thereof into the hole B. The position of the overlabel with its holes A and B, and the swab well cooperate to hold the swab in a proper position during the assay and to promote the expulsion of sorbed liquid from the swab.
  • A preassembled test strip (marked C on FIG. 1) described below, is inserted into the recess (labeled 2 on FIG. 1) and held in place by an adhesive applied to the bottom thereof. An overlabel shown in FIG. 1B is placed atop the left-hand side. It has been equipped with a single hole (marked D in FIG. 1B) which mates to the right-hand side hole A when the device is closed for performance of the assay.
  • The assembled device is stored in a sealed pouch with desiccant until it is used. Prior to sealing the pouch and storing, a lightly adhesive tape is placed on the outer edge of the right-hand half of the device.
  • B. Construction and Preparation of the Test Strip:
  • FIG. 1C shows the construction of the preassembled strip. It is comprised of a conjugate pad of sorbent material in which a conjugate of gold particles and the antigen-specific rabbit anti-S. pneumoniae C-polysaccharide antigen antibodies described above have been impregnated. A bridge pad of Ahistrom 1281 (not shown) connects the conjugate pad to a nitrocellulose pad onto which a capture line for the sample which reacts with the conjugate has been established by embedding a stripe of antigen-specific rabbit anti-S. pneumoniae C-polysaccharide antigen antibodies, prepared as described above. The nitrocellulose pad also has a downstream control line established by striping the pad with goat anti-rabbit immunoglobulin (IgG). Following the nitrocellulose pad, the strip is ended by an absorbent pad which serves as a reservoir for liquid. All of these pads are backed by an adhesive strip and placed into a device.
  • The conjugate pad is normally made from non-woven polyester or extruded cellulose acetate. To prepare this pad for use in the assay, gold particles of 50 nm. diameter are conjugated to affinity-purified rabbit anti-S. pneumoniae C-polysaccharide antibodies prepared as described above. The conjugation is effected using a known method such as that described by DeMay in Polak, J. M. and Van Norden, S. (Eds.), Immunochemistry: Modern Methods and Application, (Wright, Bristol, England, 1986). The gold conjugate particles are mixed with a drying agent consisting of aqueous 5 mM sodium tetraborate of pH 8.0 containing 1.0 percent BSA, 0.1 percent Triton X-100, 2.0 percent Tween 0.20, 6.0 percent sucrose and 0.02 percent sodium azide. The pad is heated sufficiently to remove all of the liquid present and stored in a low-humidity environment pending assembly of the test strip. These pads and their treatment are especially chosen so that the pads will hold the dry conjugate and will release it only when later wetted by sample.
  • The nitrocellulose pad is first treated by embedding a stripe of affinity purified rabbit anti-S. pneumoniae C-polysaccharide antibodies in a first portion thereof, using a carrier solution of phosphate buffered saline. These antibodies act as the capture line. In a second portion of the pad downstream of the first one in the assembled test device, the control line is established by striping goat anti-rabbit IgG in the same carrier solution on the surface of the pad. The nitrocellulose pad is then subjected to desiccation at 18-25° C. to promote permanent absorption of the protein stripes thereto.
  • The absorbent pad used is of a commercially available cellulosic material sold under the name Ahlstrom 939. This pad requires no special treatment.
  • C. Kit Preparation:
  • As sold in commerce, the test device containing the finished test strip is assembled. In practice, a number of devices are packaged with a commensurate number of swabs fashioned from fibrous Dacron and a bottle of “Reagent A” equipped with a top adapted to deliver Reagent A dropwise. “Reagent A” is a solution of 2.0 percent Tween 20, 0.05 percent sodium azide and 0.5 percent sodium dodecyl sulfate in a 0.05 M sodium citrate-sodium phosphate buffer of pH 6.5. Positive and negative controls are also included in each kit.
  • EXAMPLE #6 Conducting the ICT Assay
  • In practice, the swab furnished with each device is dipped into the liquid sample, completely immersing the swab head. The use of the swab to act as a filter for undissolved solids, semisolids and colloids present in liquid biological samples such as urine, blood, lymph, etc., and also in liquid environmental samples is the subject of copending, commonly assigned, application Ser. No. 09/044,677, now U.S. Pat. No. 6,548,309, of Norman Moore and Vincent Sy filed Mar. 19, 1998, which is assigned to Binax, Inc. The swab is inserted into the hole at the bottom of the device (hole B of FIG. 1A) and gently pushed upward so that the swab tip is visible in the top hole (hole A of FIG. 1A). The Reagent A vial is held vertically above hole B and three drops of Reagent A are slowly added. The adhesive liner is then immediately peeled from the right edge of the device and the device is closed and securely sealed, thus pressing the swab in the swab well against the gold conjugate pad. After 15 minutes, the result can be read in the window of the device. A negative sample—i.e., one not containing identifiable S. pneumoniae C-polysaccharide antigen—will exhibit only the control line in the top half of the window. A positive sample containing the target antigen will show two lines, the lower one of which is the patient (or sample) line; even a faint sample line indicates the presence of the target antigen in the sample. If no line appears in the window after 15 minutes, or only a sample line appears in the lower part of the window, the test is invalid and must be repeated.
  • Using the procedure described above, the devices prepared as described in Example 5 were tested using the ICT procedure just described against 146 patient urine samples obtained from Centers for Disease Control. Since the patient diagnoses relative to the presence of S. pneumoniae infection were based on a variety of different indications including blood culture, Gram stain, sputum culture, Autolysin PCR and Pneumolysin PCR, but urine assay results had not been made, each of these samples was tested in our laboratory with ICT as herein described and also with ELISA, for the presence of S. pneumoniae C-polysaccharide antigen.
  • Personnel performing the ICT and ELISA assays were not apprised of the Centers for Disease Control classifications of the urine samples as having been collected from patients diagnosed as positive or negative for S. pneumoniae infection. It was found that the ICT and ELISA results were, at the very least, comparable in terms of both sensitivity and specificity in some 134 instances. It is noted, however, that in some instances neither the ELISA nor the ICT tests could be fully correlated to the patient diagnoses supplied by Centers for Disease Control. It is believed that the art-recognized inadequacies of culture evaluation as a basis for diagnosis of S. pneumoniae infection and the fact that no information was available concerning either the therapy administered to any of the patients, or the time therapy was commenced relative to the time the urine sample was collected are factors that preclude any completely meaningful comparison of all the results.
  • The substantial comparability of ICT and ELISA results in 134 instances confirms the considerable advantages that the 15-minute ICT test of this invention offers in terms of rapid diagnosis of S. pneumoniae-caused infection and consequent early institution of the most effective patient therapy.
  • EXAMPLE #7 Clinical Trials
  • Using the devices prepared as described in Example 5 and the ICT procedure as described in Example 6, first paragraph, clinical studies were conducted at three sites, using a bank of characterized specimens. These included 273 urine specimens collected from hospitalized patients and outpatients. Among the 273 patients, 35 gave positive blood culture results and 238 gave negative blood culture results. (It should be noted that culture methods often vary substantially from place to place. The urine samples of the blood culture positive patients were presumed to have been collected within 24 hours of both blood collection and initial administration of antibiotics. Of the 238 urine samples from patients with blood that tested negative in blood culture tests, 28 were collected from bacteremic patients, 4 from patients with empyema, 53 from patients with pnemonia and 153 from patients with urinary tract infections).
  • In addition, 100 urine samples, which were collected from individuals with no known infection, were assayed in the test of this invention, involving the devices prepared as in Example 5 and the ICT procedure described in Example 6. Blood samples from these individuals gave negative results in culture tests.
  • Of the 35 urines from patients testing positive for S. pneumoniae in blood culture tests, 30 gave positive results in the test of this invention and 5 gave negative results. Of the 338 urine samples from patients, all of whom tested negative in blood culture tests and 100 of whom were presumed negative, 21 tested positive in the ICT test of this invention and 317 tested negative. The sensitivity of the ICT test was calculated as 86%, the specificity as 94% and the accuracy as 93%.
  • It should be noted that of the patients whose urine tested positive for S. pneumoniae by ICT and whose blood cultures gave negative results for S. pneumoniae, it was established by other tests that of those with urinary tract infections 5 had E. coli infections, 2 had Enterobacter cloacae infections, 3 had lactobacillus infections, 1 was infected with Providencia Stuartii, 1 with Staphylococcus aureus, 1 with Streptococcus (non A, nonB) and 1 with a Streptococcus (nonD) infection. Two of those who had pneumonia also were infected with Mycobacterium tuberculosis and one with Mycobacterium kansasii. One bacteremic patient was infected also with Proteus mirabilis. Four patients with no known infection had urine samples that tested positive with the ICT test of this invention.
  • EXAMPLE #8 Clinical Trials
  • Tests were conducted at seven hospitals, six in the United States and one in Spain to evaluate 215 urine specimens from both hospitalized and outpatients with at least one of lower respiratory symptoms and sepsis symptoms or who were otherwise suspected of harboring pneumococcal pneumonia. In these tests, the device prepared in accordance with Example 5 was utilized in the procedure of Example 6 and the results were compared with blood culture results conducted on blood specimens from the same patients. No effort was made to assure uniformity of culture methods among the participating institutions.
  • The blood culture results yielded 31 positive assessments for S. pneumoniae and 184 negative assessments. Of the 31 patients whose blood culture results were positive, the ICT test of this invention conducted on urine samples showed 28 positives and 3 negatives. Of the 184 patients whose blood culture results were as assessed negative, 45 provided urine samples that tested positive in the ICT test of this invention while 139 urine samples from these patients tested negative. Sensitivity in this trial for the test of the invention was calculated as 90%, specificity as 76% and accuracy as 78%.
  • The results obtained with the ICT tests of this invention in Examples 7 and 8 must be considered in the light of the well-known problems associated with culture tests and the known likelihood that about 80% of patients infected with pneumococcal pneumonia will not produce blood specimens that contain S. pneumoniae. It is believed that further experience with the assay of this invention will demonstrate convincingly that its specificity, sensitivity and accuracy are understated in Examples 7 and 8 due to the use of blood culture tests for comparison purposes.
  • EXAMPLE #9 Further Cross-Reactivity Testing
  • Using the device prepared as in Example 5 and the procedure of Example 6, some 144 organisms at concentrations of 106 to 109 CFU/mL were tested. Each of the organisms tested was grown on appropriate agar and incubated at 37° C. in 5% CO2 overnight, whereupon the plates were checked for purity and well isolated colonies of each organism were selected for testing.
  • Of the 144 organisms, only one—S. mitis—A.T.C.C. #49456, gave a positive test and hence was cross-reactive. This was expected, as noted above, because S. mitis is known to contain the C-polysaccharide cell wall antigen which the test of this invention is designed to detect.
  • Negative results in the assay of the invention were obtained with each of the following: Acinetobacter anitratus (ATCC #49139) Acinetobacter baumanii (ATCC # 1906-T), Acinetobacter calcoaceticus (ATCC No. 49466), Acinetobacter haemolyticus (A.T.C.C. # 19002), Adenovirus 2 and 3 (pooled pure culture sample obtained from Center for Disease Control), Alcaligenes faecalis (A.T.C.C. # 6633), Bordetella pertussis (A.T.C.C. # 3467), Branhamella catarrhalis (A.T.C.C. # 25238-T), Blastonyces dernatitidis (pure culture obtained from Center for Disease Control, strain number unknown), Candida albicans (A.T.C.C. #'s e10231, 14053 and 60193, each tested separately), Candida stellatoides (A.T.C.C. #11006), Citrobacter freundii (A.T.C.C. #375GT), Coccidiodes immitis (pure culture from Center for Disease Control, strain number unknown), Corynebacterium kutscheri (A.T.C.C. # 15677-T), Corynebacterium matruchotii (A.T.C.C. # 14266-T), Corynebacterium pseudodipheriticum (A.T.C.C. 10700-T), Enterobacter cloacae (A.T.C.C. #'s 13047-T, 23355, 35030 and 49141, each tested separately), Enterococcus avium (A.T.C.C. No. 49462), Enterococcus durans (A.T.C.C. # 49135), Enterococcus faecalis (A.T.C.C. #'s 19433-T, 29212, 49477, 49478, 49149 and 51299, each tested separately), Escherichia coli (A.T.C.C. #'s 23513, 8739, 23514, 25922, 35218, 1173GT, 35421 and 15669 and one unnumbered sample, each tested separately), Escherichia hermannii (A.T.C.C. #'s 33650-T and 4648GT, each tested separately), Flavobacterium indologenes (A.T.C.C. # 49471), Flavobacterium meningosepticum (A.T.C.C. # 49470), Gardnerella vaginalis (A.T.C.C. # 14018-T), Haemophilus influenzae, a (A.T.C.C. # 9006), Haemophilus influenzae, b (A.T.C.C. #'s 9795 and 33533, each tested separately), Haemophilus influenzae, c (A.T.C.C. # 9007), Haemophilus influenzae, d (A.T.C.C. # 9008), Haemophilus influenzae, e (A.T.C.C. # 8142), Haemophilus influenzae, f (A.T.C.C.# 9833, Haemophilus influenzae, NT (A.T.C.C. #'s 49144, 49247 and 49766, each tested separately), Haemophilus parainfluenzae (A.T.C.C. # 3339Z-T, obtained as a pure culture from Center for Disease Control), Histoplasma capulatum (Two separate pure cultures from Center for Disease Control, strains unknown, each tested separately), Klebsiella oxytoca (A.T.C.C. #'s 43086 and 49131, each tested separately), Klebsiella pneumoniae (A.T.C.C. #'s 13882, 13883-T and 49472, each tested separately), Lactobacillus acidophilus (A.T.C.C. # 4356), Lactobacillus casei (A.T.C.C. # 393), Lactobacillus gasseri (A.T.C.C. # 33323), Lactobacillus jensenii (A.T.C.C. # 25258), Legionella pneumophila (A.T.C.C. # 33152), Listeria monocytogenes (A.T.C.C. # 7644), Micrococcus luteus (A.T.C.C. #'s 9341 and 49732, each tested separately), Moraxella ostoensis (A.T.C.C. # 15276), Morganella morganii (A.T.C.C. # 25830-T), Mycoplasma genitalium (A.T.C.C. # 33530, obtained as a pure culture from Center for Disease Control), Mycoplasma hominis (A.T.C.C. # 27545, obtained as a pure culture from Center for Disease Control), Mycoplasma pneumoniae (FH Type 2, obtained as a pure culture from Center for Disease Control), Neisseria cinerea (A.T.C.C. # 14685), Neisseria gonorrheae (A.T.C.C. #'s 8660, 19424-T and 27631, each tested separately), Neisseria lactamica (A.T.C.C. # 23970-T), Neisseria meningitidis (A.T.C.C. # 13077-T), Neisseria subflava (A.T.C.C. # 49275), Nocardia farcinia (obtained as a pure culture from Center for Disease Control), Paracoccidiodes brasiliensis (strain # unknown, obtained as a pure culture from Center for Disease Control), Parainfluenzae Type 1 (strain C 39, obtained as a pure culture from Center for Disease Control), Parainfluenzae Type 2 (strain H A 47885, obtained from Center for Disease Control as a pure culture), Proteus mirabilis (A.T.C.C. #'s 7002 and 12453, each tested separately), Proteus vulgaris (A.T.C.C. #'s 13315-T and 49132, each tested separately), Providencia stuartii (A.T.C.C. # 49809), Pseudomonas aeruginosa (A.T.C.C. #'s 15442 and 27853, each tested separately), Pseudomonas cepacia (A.T.C.C. # 25416-T), Pseudomonas pickettii (A.T.C.C. # 49129), Pseudomonas putida (A.T.C.C. # 49128), Pseudomonas putrefaciens (A.T.C.C. # 49138), Pseudomonas stutzeri (A.T.C.C. # 17588-T), Respiratory Syncitial Virus, pooled (Pooled sample of Strain A2 and A.T.C.C. # 18573, each obtained from Center for Disease Control as a pure culture), Rhinovirus (A.T.C.C. #'s 088 and 077, each obtained as a pure culture from Center for Disease Control and each tested separately), Salmonella cubana (A.T.C.C. # 12007), Salmonella enteritidis (A.T.C.C. # 13076-T), Salmonella paratyphi A (A.T.C.C. # 9150), Salmonella typhi (A.T.C.C. # 6539), Serratia marcescens (A.T.C.C. # 13880-T), Sphingobacterium multivorum (A.T.C.C. # 35656), Staphylococcus aureus (A.T.C.C. #'s 12598, 6538P, 25923, 29213, 43300 and 49476, each tested separately), Staphylococcus epidermidis (A.T.C.C. #'s 12228, 14990-T, 49134, and 49461, each tested separately), Staphylococcus haemolyticus (A.T.C.C. # 29970-T), Staphylococcus saprophyticus (A.T.C.C. #'s 15305-T and 49907, each tested separately), Staphylococcus xylosis (A.T.C.C. # 49148), Stenotrophomonas maltophilia (A.T.C.C. # 13637-T), Streptococcus anginosus (A.T.C.C. # 9895), Streptococcus bovis (A.T.C.C. # 49133), Streptococcus Group A (A.T.C.C. #'s 1357, and 19615, each tested separately), Streptococcus Group B (A.T.C.C. #'s 13813-T, 12386, 12400, 12401, 27591, 12973, 12403, and 31475, each tested separately), Streptococcus Group C (A.T.C.C. # 12388), Streptococcus Group F (A.T.C.C. # 12392), Streptococcus Group G (A.T.C.C. 12394), Streptococcus mutans (Shockman strain), Streptococcus parasanguis (A.T.C.C. # 15909), Streptococcus sanguis (A.T.C.C. # 10556-T), Trichomonas vaginalis (A.T.C.C. #'s 085 and 520, each obtained as a pure culture from Center for Disease Control and tested separately).
  • EXAMPLE #10 Clinical Trial with Healthy and Sick Children
  • An as yet unfinished clinical trial with healthy and sick children as participants is in progress. Preliminary spot results show that, using devices prepared as described in Example 5 and following the procedure described in Example 6, S. pneumoniae was detected in urine of 2 of 3 children diagnosed with sinusitis. It is believed that the sinusitis case wherein the child's urine tested negative may involve a different causative agent.
  • In the same trials, S. pneumoniae was detected with the device and method of this invention in the cerebrospinal fluid of the only child who exhibited overt signs of meningitis, enabling prompt and effective therapeutic treatment of this individual.
  • EXAMPLE #11 Detection of S. Pneumoniae Antigen in Urine of Meningitis Patients
  • Two patients exhibiting overt clinical symptoms of meningitis were hospitalized. One had received antimicrobial therapy prior to admission; the other had not. From each, cerebrospinal fluid was obtained and subjected to a culture test. The test results were negative, and so were blood culture results.
  • As a last diagnostic resort, devices prepared according to Example 6 were utilized in the procedure described in Example 7 on urine samples obtained from each patient. In each case, the urine samples tested positive for the S. pneumoniae C-polysaccharide cell wall antigen.
  • These preliminary results strongly suggest that urine samples may be routinely utilized in lieu of cerebrospinal fluid to test for S. pneumoniae-caused meningitis. The ability to substitute urine for cerebrospinal fluid as a test medium, if confirmed by further clinical experience, will be of great benefit to patients and medical practitioners alike. Spinal taps, by which cerebrospinal fluid must be obtained, are painful for patients and somewhat hazardous as well. For medical practitioners, spinal taps are time consuming and require concentrated attention to detail.
  • Those skilled in the art of immunochemistry generally, and especially those skilled in immunoassays, will recognize that other materials and ingredients and at times, other procedural steps, can readily be substituted for those specifically recommended herein. A vast array of literature, both patent and non-patent, discusses the design and use of reliable, one-time-use, disposable immunoassay test devices that could be substituted for the preferred ICT device described and recommended herein. It is not intended that the present invention should be limited with respect to substitutable assay devices, materials, ingredients or process steps except insofar as the following claims may so limit it.

Claims (4)

1. A cell wall C-polysaccharide antigen of Streptococcus pneumoniae which contains not more than 10% by weight of protein which has been obtained by
a) subjecting a culture of S. pneumoniae to a treatment which kills the bacterial cells,
b) separating the killed bacteria cells as a cell pellet of weakly alkaline pH in the order of from about 7.0 to 7.4,
c) subjecting the pellet of step (b) to incubation with a sufficient quantity of 0.1 N NaOH to elevate its pH to a value in excess of 12.0 for a period of at least 45 minutes,
d) deproteinizing the mixture, and
e) separating out a purified cell wall C-polysaccharide antigen containing not more than about 10% by weight of protein.
2. A cell wall C-polysaccharide antigen of Streptococcus pneumoniae according to claim 1 containing from 5 to 8% by weight of protein wherein the bacterial cells in step (a) were killed by a sodium azide treatment.
3. Polyvalent antibodies raised in an animal against Streptococcus pneumoniae bacteria or their cell wall C-polysaccharide antigen which have been affinity purified and thereby rendered antigen specific by passing them over a chromatographic affinity column on which the affinity gel is wholly comprised of a non-ion exchange material to which has been coupled the cell wall C-polysaccharide antigen of claim 1.
4. Polyvalent antibodies raised in an animal against Streptococcus pneumoniae bacteria or their cell wall C-polysaccharide antigen which have been affinity purified and thereby rendered antigen specific by passing them over a chromatographic affinity column on which the affinity gel is wholly comprised of a non-ion exchange material to which has been coupled the cell C-polysaccharide antigen of claim 2.
US11/982,410 1998-09-18 2007-10-31 Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies Abandoned US20080241191A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US15648698A true 1998-09-18 1998-09-18
US09/397,110 US6824997B1 (en) 1998-09-18 1999-09-16 Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US10/989,050 US20050148039A1 (en) 1998-09-18 2004-11-16 Process and materials for the rapid detection of Streptococcus pneumoniae employing purified antigen-specific antibodies
US11/740,738 US20070265433A1 (en) 1998-09-18 2007-04-26 Process and Materials for the Rapid Detection of Streptococcus Pneumoniae Employing Purified Antigen-Specific Antibodies
US11/982,410 US20080241191A1 (en) 1998-09-18 2007-10-31 Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/982,410 US20080241191A1 (en) 1998-09-18 2007-10-31 Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US14/628,827 US9310369B2 (en) 1998-09-18 2015-02-23 Process and materials for the rapid detection of Streptococcus pneumoniae employing purified antigen-specific antibodies
US15/057,822 US9921220B2 (en) 1998-09-18 2016-03-01 Process and materials for the rapid detection of Streptococcus pneumoniae employing purified antigen-specific antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/740,738 Continuation US20070265433A1 (en) 1998-09-18 2007-04-26 Process and Materials for the Rapid Detection of Streptococcus Pneumoniae Employing Purified Antigen-Specific Antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/628,827 Continuation US9310369B2 (en) 1998-09-18 2015-02-23 Process and materials for the rapid detection of Streptococcus pneumoniae employing purified antigen-specific antibodies

Publications (1)

Publication Number Publication Date
US20080241191A1 true US20080241191A1 (en) 2008-10-02

Family

ID=33449075

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/397,110 Expired - Lifetime US6824997B1 (en) 1998-09-18 1999-09-16 Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US11/982,410 Abandoned US20080241191A1 (en) 1998-09-18 2007-10-31 Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US14/628,827 Expired - Lifetime US9310369B2 (en) 1998-09-18 2015-02-23 Process and materials for the rapid detection of Streptococcus pneumoniae employing purified antigen-specific antibodies
US15/057,822 Expired - Lifetime US9921220B2 (en) 1998-09-18 2016-03-01 Process and materials for the rapid detection of Streptococcus pneumoniae employing purified antigen-specific antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/397,110 Expired - Lifetime US6824997B1 (en) 1998-09-18 1999-09-16 Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/628,827 Expired - Lifetime US9310369B2 (en) 1998-09-18 2015-02-23 Process and materials for the rapid detection of Streptococcus pneumoniae employing purified antigen-specific antibodies
US15/057,822 Expired - Lifetime US9921220B2 (en) 1998-09-18 2016-03-01 Process and materials for the rapid detection of Streptococcus pneumoniae employing purified antigen-specific antibodies

Country Status (3)

Country Link
US (4) US6824997B1 (en)
JP (2) JP2012006929A (en)
CN (1) CN1769295B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113056A1 (en) * 2010-03-12 2011-09-15 The Trustees Of The University Of Pennsylvania Methods for preventing and treating staphylococcus aureus colonization, infection, and disease
WO2015200626A1 (en) * 2014-06-25 2015-12-30 The Rockefeller University Compositions and methods for rapid production of versatile nanobody repertoires
US9958453B2 (en) 2015-03-10 2018-05-01 National Chiao Tung University Biological sensing method for separating biomolecule

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US20080096236A1 (en) * 1998-08-25 2008-04-24 Binax, Inc. Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US6916626B1 (en) * 2001-04-25 2005-07-12 Rockeby Biomed Ltd. Detection of Candida
JP2005515214A (en) * 2001-10-15 2005-05-26 カイロン コーポレイション Treatment of sepsis due to low amount of administration of tissue factor pathway inhibitor (TFPI)
US7718375B2 (en) * 2002-02-27 2010-05-18 Binax, Inc. Modification of bioassays for detection of antigens characteristic of bacteria that are causative of ear and respiratory infections to eliminate false positive results caused by nasopharyngeal colonization of children
WO2005063973A1 (en) * 2003-11-26 2005-07-14 Binax, Inc. Methods and kits for predicting an infectious disease state
US20050272106A1 (en) * 2004-02-17 2005-12-08 Norman Moore Methods and kits for detection of multiple pathogens
AU2005244249A1 (en) * 2004-03-17 2005-11-24 Novartis Vaccines And Diagnostics, Inc. Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (TFPI)
US7387890B2 (en) 2004-12-16 2008-06-17 Chembio Diagnostic Systems, Inc. Immunoassay devices and use thereof
WO2006098804A2 (en) 2005-03-11 2006-09-21 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
US7189522B2 (en) 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
US8153444B2 (en) * 2005-10-13 2012-04-10 Auric Enterprises, Llc Immuno gold lateral flow assay
US7344893B2 (en) * 2005-10-13 2008-03-18 Auric Enterprises, Llc Immuno-gold lateral flow assay
US7910381B2 (en) * 2005-10-13 2011-03-22 BioAssay Works Immuno gold lateral flow assay
US20080014657A1 (en) * 2006-07-12 2008-01-17 Beckton Dickinson And Company Use of Albumin, Bovine, P-Aminophenyl N-Acetyl B-D Glucosaminide as a Control Line for an Immunoassay Device
CN101517095A (en) * 2006-09-26 2009-08-26 爱科来株式会社 Method for formation of reagent layer in analysis apparatus, method for manufacture of analysis apparatus, and analysis apparatus
US8247220B2 (en) * 2008-02-01 2012-08-21 Kimberly-Clark Worldwide, Inc. Optical indicator for detecting bacterial pathogens
US8241857B2 (en) * 2008-03-31 2012-08-14 Otsuka Pharmaceutical Co., Ltd. Method for detection of pneumococcus
WO2010075265A2 (en) 2008-12-23 2010-07-01 The Government Of The United States Of America , As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Lung aerosol collection device
US8603835B2 (en) 2011-02-10 2013-12-10 Chembio Diagnostic Systems, Inc. Reduced step dual path immunoassay device and method
KR20140145137A (en) 2012-03-30 2014-12-22 오츠카 세이야쿠 가부시키가이샤 Method for determining severity of pneumococcal pneumonia
MX2016012881A (en) 2014-04-02 2017-05-10 Chembio Diagnostic Systems Inc Immunoassay utilizing trapping conjugate.
US20160033505A1 (en) * 2014-07-31 2016-02-04 Laborie Medical Technologies Canada Ulc Mobile Phase Test Strip Components, Conjugate Pad Pre-treatment Solutions, And Related Methods Thereof

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703017A (en) * 1984-02-14 1987-10-27 Becton Dickinson And Company Solid phase assay with visual readout
US4751190A (en) * 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US4888279A (en) * 1984-12-21 1989-12-19 Thomas Jefferson University Novel immunosorbent assays employing antibiotic keying agents
US4954449A (en) * 1982-08-24 1990-09-04 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibody reactive with polyribosylribitol phosphate
US5139933A (en) * 1989-09-26 1992-08-18 Vicam, L.P. Assay method for detecting listeria
US5455032A (en) * 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
US5455302A (en) * 1992-12-28 1995-10-03 Ge Plastics Japan Thermoplastic resin compositions
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5665561A (en) * 1994-06-06 1997-09-09 The Rockefeller University Modulators of pneumococcal adherence to pulmonary and vascular cells and diagnostic and therapeutic applications
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5866140A (en) * 1991-11-22 1999-02-02 Nabi Type I surface antigen associated with staphylococcus epidermidis
US5871951A (en) * 1996-09-23 1999-02-16 The Children's Hospital Of Philadelphia Compositions and methods for treatment of infection caused by Haemophilus influenzae and Streptococcus pneumoniae
US5989542A (en) * 1997-08-20 1999-11-23 Brigham And Women's Hospital, Inc. Capsular polysaccharides from enterococci
US6057421A (en) * 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US6217866B1 (en) * 1988-09-15 2001-04-17 Rhone-Poulenc Rorer International (Holdings), Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US6566500B1 (en) * 1999-03-30 2003-05-20 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
US20030157115A1 (en) * 1997-03-27 2003-08-21 Sylvie Bay Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US20040247605A1 (en) * 2002-12-02 2004-12-09 Kokai-Kun John Fitzgerald Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
US20060121058A1 (en) * 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
US7169903B2 (en) * 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20090186368A1 (en) * 1999-02-05 2009-07-23 Neil David Hammond Raven Assay with reduced background
WO2009122714A1 (en) * 2008-03-31 2009-10-08 大塚製薬株式会社 Method for detection of pneumococcus

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206094A (en) 1976-06-09 1980-06-03 California Institute Of Technology Method for producing a biological reagent
US4411832A (en) 1979-11-26 1983-10-25 Pedro Cuatrecasas Polysaccharide matrices comprising macromolecular spacer arms for use as adsorbents in affinity chromatography techniques
NL8000173A (en) * 1980-01-11 1981-08-03 Akzo Nv Use of water-dispersible, hydrophobic dyes as labels in immunochemical assays.
US4514509A (en) 1981-09-21 1985-04-30 Indiana University Foundation Method for the diagnosis of Legionnaires' disease
FR2541304B1 (en) 1983-02-21 1985-05-17 Centre Nat Rech Scient
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
DE3445816C1 (en) * 1984-12-15 1986-06-12 Behringwerke Ag Flaechenfoermiges diagnostic tool
US5879881A (en) * 1985-04-04 1999-03-09 Hybritech, Incorporated Solid phase system for use in ligand-receptor assays
TW203120B (en) * 1985-10-04 1993-04-01 Abbott Lab
ES2050704T5 (en) * 1987-04-27 2004-04-16 Inverness Medical Switzerland Gmbh Immunoassays and devices for its realization.
US4943522A (en) * 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5098827A (en) * 1988-02-26 1992-03-24 The University Of Florida Novel bacterial markers for pathogenic group B streptococci
US5075078A (en) 1989-10-05 1991-12-24 Abbott Laboratories Self-performing immunochromatographic device
US5198339A (en) 1990-07-13 1993-03-30 Board Of Regents, The University Of Texas System Method for detection of gram-negative bacterial lipopolysaccharides in biological fluids
NZ239643A (en) 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5843463A (en) 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
ES2131066T3 (en) 1990-12-21 1999-07-16 Antex Biolog Inc Oligosaccharide conjugate vaccine with adhesin for hi (haemophilus influenzae).
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US6168956B1 (en) 1991-05-29 2001-01-02 Beckman Coulter, Inc. Multiple component chromatographic assay device
JP3176659B2 (en) 1991-09-05 2001-06-18 本田技研工業株式会社 Electric car
JPH07503543A (en) * 1992-02-04 1995-04-13
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
WO1994029696A1 (en) * 1993-06-09 1994-12-22 Quidel Corporation Antigen-specific one-step assays
US5415994A (en) * 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5367058A (en) 1993-08-25 1994-11-22 Becton, Dickinson And Company Modified antibodies with increased affinity
EP0804582A1 (en) * 1994-05-16 1997-11-05 The Uab Research Foundation $i(STREPTOCOCCUS PNEUMONIAE) CAPSULAR POLYSACCHARIDE GENES AND FLANKING REGIONS
FR2746316B1 (en) 1996-03-19 1998-06-12 Guerlain New Facial care or dermatological compositions
DE69724515D1 (en) * 1996-06-07 2003-10-09 Oxoid Ltd Apparatus and test set to the test of serum, and the like
AUPO071396A0 (en) 1996-06-28 1996-07-25 Chandler, Howard Milne Chromatographic assay or test device
JP3517808B2 (en) 1996-07-17 2004-04-12 日本酸素株式会社 Vapor-phase growth method and apparatus
US5798273A (en) * 1996-09-25 1998-08-25 Becton Dickinson And Company Direct read lateral flow assay for small analytes
US6194221B1 (en) * 1996-11-19 2001-02-27 Wyntek Diagnostics, Inc. Hybrid one-step immunochromatographic device and method of use
JP3411186B2 (en) 1997-06-06 2003-05-26 シャープ株式会社 Nonvolatile semiconductor memory device
US6979576B1 (en) * 1997-07-25 2005-12-27 Shu-Ching Cheng Methods of use of one step immunochromatographic device for Streptococcus A antigen
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
AT293457T (en) * 1998-09-18 2005-05-15 Binax Inc Procedures and materialienzur rapid detection of streptocuccos pneumoniae using purified antigen-specific antibody
US6495139B2 (en) * 1998-11-19 2002-12-17 St. Jude Children's Research Hospital Identification and characterization of novel pneumococcal choline binding protein, CBPG, and diagnostic and therapeutic uses thereof
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US7718375B2 (en) * 2002-02-27 2010-05-18 Binax, Inc. Modification of bioassays for detection of antigens characteristic of bacteria that are causative of ear and respiratory infections to eliminate false positive results caused by nasopharyngeal colonization of children
EP2081953A2 (en) * 2006-08-17 2009-07-29 The UAB Research Foundation Immunogenic pcpa polypeptides and uses thereof
CN101021526B (en) * 2007-03-16 2012-01-25 艾博生物医药(杭州)有限公司 Apparatus and method for visual display of detecting result
EP3096785A2 (en) * 2014-01-21 2016-11-30 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Patent Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954449A (en) * 1982-08-24 1990-09-04 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibody reactive with polyribosylribitol phosphate
US4703017C1 (en) * 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
US4703017A (en) * 1984-02-14 1987-10-27 Becton Dickinson And Company Solid phase assay with visual readout
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4888279A (en) * 1984-12-21 1989-12-19 Thomas Jefferson University Novel immunosorbent assays employing antibiotic keying agents
US4751190A (en) * 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US6217866B1 (en) * 1988-09-15 2001-04-17 Rhone-Poulenc Rorer International (Holdings), Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5139933A (en) * 1989-09-26 1992-08-18 Vicam, L.P. Assay method for detecting listeria
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5866140A (en) * 1991-11-22 1999-02-02 Nabi Type I surface antigen associated with staphylococcus epidermidis
US5455302A (en) * 1992-12-28 1995-10-03 Ge Plastics Japan Thermoplastic resin compositions
US5455032A (en) * 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
US5665561A (en) * 1994-06-06 1997-09-09 The Rockefeller University Modulators of pneumococcal adherence to pulmonary and vascular cells and diagnostic and therapeutic applications
US6057421A (en) * 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US5871951A (en) * 1996-09-23 1999-02-16 The Children's Hospital Of Philadelphia Compositions and methods for treatment of infection caused by Haemophilus influenzae and Streptococcus pneumoniae
US20030157115A1 (en) * 1997-03-27 2003-08-21 Sylvie Bay Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US5989542A (en) * 1997-08-20 1999-11-23 Brigham And Women's Hospital, Inc. Capsular polysaccharides from enterococci
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US20090186368A1 (en) * 1999-02-05 2009-07-23 Neil David Hammond Raven Assay with reduced background
US6566500B1 (en) * 1999-03-30 2003-05-20 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
US7169903B2 (en) * 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20060121058A1 (en) * 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
US20040247605A1 (en) * 2002-12-02 2004-12-09 Kokai-Kun John Fitzgerald Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
WO2009122714A1 (en) * 2008-03-31 2009-10-08 大塚製薬株式会社 Method for detection of pneumococcus

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
AlonsoDeVelasco, E et al, Microbiological Reviews, Dec. 1995, pages 591-603, vol. 59(4), Streptococcus pneumoniae: Virulence Factors, pathogenesis and vaccines. *
Au, CC et al, Infection and Immunity, 1981, vol. 31(1), pages 169-173, Evaluation of the role of the pneumococcal Forssman antigen (F-polysaccharide) in the cross-serotype protection induced by pneumoccal subcellular preparations. *
Benzing, Laure, Infection and Immunity, 1981, June, vol. 32(3), pages 1024-1027, Specific Capsular Polysaccharide of Type 46 Streptococcus pneumoniae (American type 73). *
Bromberg et al (1990), reference already of record. *
Brundish, D.E. et al, Biochemical Journal, 1968, vol. 110, pages 573-582, Pneumococcal C-Substance, A Ribitol Teichoic Acid Containing Choline Phosphate. *
Coligan, John E. et al, The Journal of Immunology, vol. 118(1) January 1977, pages 6-11, A disaccharide hapten from Streptococcal Group C Carbohydrate that Cross-reacts with the Forssman Glycolipid. *
Fischer, W et al (1993), European Journal of Biochemistry, vol. 215, pagtes 851-857, Teichoic acid and lipoteichoic acid of Streptococcus pnuemonoiae possess identical chain structures. *
Hogg, Stephen D et al, International Journal of Systematic Bacteriology, Jan 1997, pages 62-66, vol. 47(1), Occurrence of Lipoteichoic acid in Oral Streptococci. *
Klein, Roger A et al, Carbohydrate Research, vol. 256(2), April 1, 1994, pages 189-222, The aqueous solution structure of the tetrasaccharide-ribitol repeating unit from the lipoteichoic acid of Streptococcus pneumoniae strain R6 determined using a combination of NMR spectroscopy and computer calculations. *
Kolkman, Marc A. B et al, Journal of Biological Chemistry, 1997, vol. 272(31), pages 19502-19508, 1997, Functional Analysis of Glycosyltransferases encoded by the Capsular polysaccharide Biosyntheisi Locus of Streptococcus pneumoniae Serotype 14. *
Kovacs et al, August 2006, pages5797-5805, vol. 188(16), August, Journal of Bacteriology, A Functional dlt operon, encoding proteins required for incorporation of D-alanine in Teichoic Acids in Gram Positive Bacteria, Confers Resistance to Cationic Antimicrobial Peptides in Streptococcus pneumoniae,. *
Manjula, B.N. et al, Immunochemistry, vol. 15, pages 269-271, 1978, Affinity of horse anti-phophorylcholine antibodies for some pneumococcal polysaccharides, contribution of the polysaccharide backbone. *
Manning, James M, The Journal of Bioloigcal Chemistry, vol. 246(9), pages 2926-2929, May 10, 1971, Chromatographic Determinaton of D and L-amino acid Residues in Pneumococcal C-polysaccharide. *
Nagel, Joerg G et al, Journal of Clinical Microbiology, Sept. 1977, vol. 6(3), pages 233-237, Teichoic Acids in Pathogenic Staphylococcus aureus. *
Nowinski et al (1980), Science, vol. 210, October 31, 1980, pages 537-539, Human monoclonal antibody against Forssman Antigen. *
Sjogren, AM et al, Journal of Immunological Methods, vol. 102(1), pages 93-100, August 1987. *
Sjogren, AnnMargret et al, Diagnostic Microbiology Infectious Disese, 1988, vol. 10, pages 7-21, Demonstration of Cross-Reactions between pneumococci and alpha-streptococci using gold-lablelled mono- and polyclonal antibody and electron microscopy. *
Sorensen, Uffe B Skov et al, Infection and Immunity, August 1988, vol. 56(8), pages 1890-1896, Ultrastructural Localization of Capsules, Cell Wall POlysaccharide, Cell Wall Proteins, and F Antigen in Pneumococci. *
Stroop, Corne JM et al, Carbohydrate Research, vol. 337, pages 335-344, 2002, Structural analysis and chemical depolymerization of the capsular polysaccharide of Streptococcus pneumoniae type 1. *
Sundberg-Kovamees, M et al, Microbial Pathogenesis, 1996, vol. 21, pages 223-234, Interaction of the C-polysaccharide of Streptococcus pneumoniae with the receptor asialo-GM1. *
Szu, S.C. et al, Infection and Immunity, Nov. 1986, vol. 54(2), pages 448-455, Rabbit Antibodies to the Cell Wall Polysaccharide of Streptococcus pneumoniae Fail to Portect Mice from Lethal Challenge with Encapsulated Pneumonococci. *
Waltman III (1988) et al, Journal of Clinical Microbiology, vol. 26(9), pages 1635-1640, Cross-reactive monoclonal antibodies for diagnosis of pneumococcal meningitis. *
Yang et al, vol. 286(41), pages 35813-35822, October 14, 2011, The Journal of Biological Chemistry, Comparative Structural and Molecular Characterization of Streptococcus pneumoniae Capsular POlysaccharide Serotype 10. *
Yother, J et al,Infection and Immunity, vol. 36(1), April 1982, pages 184-188, Protection of Mice from Infection with Streptococcus pneumoniae by Anti-Phosphocholine Antibody. *
Yother, Janet et al, Journal of Bacteriology, April 1998, pages 2093-2101, vol. 180(8), Generation and Properties of a Streptococcus pneumoniae mutant which does not require choline or analogs for growth. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113056A1 (en) * 2010-03-12 2011-09-15 The Trustees Of The University Of Pennsylvania Methods for preventing and treating staphylococcus aureus colonization, infection, and disease
WO2015200626A1 (en) * 2014-06-25 2015-12-30 The Rockefeller University Compositions and methods for rapid production of versatile nanobody repertoires
US9958453B2 (en) 2015-03-10 2018-05-01 National Chiao Tung University Biological sensing method for separating biomolecule

Also Published As

Publication number Publication date
CN1769295B (en) 2011-09-14
JP5969088B2 (en) 2016-08-10
US9310369B2 (en) 2016-04-12
US9921220B2 (en) 2018-03-20
CN1769295A (en) 2006-05-10
US6824997B1 (en) 2004-11-30
JP2015180880A (en) 2015-10-15
US20150219648A1 (en) 2015-08-06
US20160377614A1 (en) 2016-12-29
JP2012006929A (en) 2012-01-12

Similar Documents

Publication Publication Date Title
Goldschneider et al. Human immunity to the meningococcus: II. Development of natural immunity
Knudsen et al. Carbenicillin: a new semisynthetic penicillin active against Pseudomonas pyocyanea.
Messner et al. Serum opsonin, bacteria, and polymorphonuclear leukocyte interactions in subacute bacterial endocarditis: Anti-γ-globulin factors and their interaction with specific opsonins
DILLON JR et al. The epidemiology of impetigo and acute glomerulonephritis: Results of serological typing of group A streptococci
Kasper The polysaccharide capsule of Bacteroides fragilis subspecies fragilis: immunochemical and morphologic definition
Ghafoor et al. Diagnoses of acute lower respiratory lhlct infections in children in Rawalpindi and Islamabad, Pakistan
Sweet et al. Microbiology and pathogenesis of acute salpingitis as determined by laparoscopy: what is the appropriate site to sample?
Karalus et al. Community acquired pneumonia: aetiology and prognostic index evaluation.
Geiseler et al. Community-acquired purulent meningitis: a review of 1,316 cases during the antibiotic era, 1954-1976
Hauser et al. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome.
Van Emmerik et al. Binding of mannan‐binding protein to various bacterial pathogens of meningitis
Mack et al. Association of biofilm production of coagulase-negative staphylococci with expression of a specific polysaccharide intercellular adhesin
Klugman Pneumococcal resistance to antibiotics.
Caprioli et al. Communitywide outbreak of hemolytic-uremic syndrome associated with non-O157 verocytotoxin-producing Escherichia coli
Woodhead et al. The value of routine microbial investigation in community-acquired pneumonia
Hardie et al. Pneumococcal pleural empyemas in children
Levin et al. Bacteremic Hemophilus influenzae pneumonia in adults: a report of 24 cases and a review of the literature
Michaels et al. Use of antiserum agar for detection of Haemophilus influenzae type b in the pharynx
Mccracken JR et al. Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis
WEINER et al. Antigen detection in the diagnosis of invasive aspergillosis: utility in controlled, blinded trials
Blakebrough et al. The epidemiology of infections due to Neisseria meningitidis and Neisseria lactamica in a northern Nigerian community
Kohler et al. Onset and duration of urinary antigen excretion in Legionnaires disease.
Demers et al. Severe invasive group A streptococcal infections in Ontario, Canada: 1987–1991
YOUNG et al. Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations
US5354661A (en) Monoclonal antibody to enterohemorrhagic Escherichia coli 0157:H7 and 026:H11 and method for detection

Legal Events

Date Code Title Description
AS Assignment

Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, MARYLAND

Free format text: SECURITY AGREEMENT;ASSIGNORS:ADVANTAGE DIAGNOSTICS CORPORATION;ALERE MEDICAL INCORPORATED;ALERE SAN DIEGO, INC.;AND OTHERS;REEL/FRAME:026557/0287

Effective date: 20110630

AS Assignment

Owner name: BINAX, INC., MAINE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOORE, NORMAN JAMES;FENT, MARY KATHLEEN;KOULCHIN, VLADIMIR ANDREI;AND OTHERS;SIGNING DATES FROM 19991115 TO 19991116;REEL/FRAME:026851/0247

Owner name: ALERE SCARBOROUGH, INC., MAINE

Free format text: CHANGE OF NAME;ASSIGNOR:BINAX, INC.;REEL/FRAME:026851/0313

Effective date: 20100701

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ISCHEMIA TECHNOLOGIES, INC., MASSACHUSETTS

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: ALERE SAN DIEGO, INC., CALIFORNIA

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: MATRIA HEALTHCARE, INC., GEORGIA

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: INSTANT TECHNOLOGIES, INC., VIRGINIA

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: AMEDITECH INC., CALIFORNIA

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: ADVANTAGE DIAGNOSTICS CORPORATION, CALIFORNIA

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: ZYCARE, INC., NORTH CAROLINA

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: INVERNESS MEDICAL - BIOSTAR INC., MASSACHUSETTS

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: ALERE SCARBOROUGH, INC., MAINE

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: ALERE MEDICAL, INC., NEVADA

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: MATRITECH, INC., MASSACHUSETTS

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: HEMOSENSE, INC., CALIFORNIA

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: CHOLESTECH CORPORATION, CALIFORNIA

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: GENECARE MEDICAL GENETICS CENTER, INC., NORTH CARO

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: BINAX, INC., MAINE

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: BIOSITE INCORPORATED, CALIFORNIA

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

Owner name: APPLIED BIOTECH, INC., CALIFORNIA

Free format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT;REEL/FRAME:036011/0581

Effective date: 20150618

AS Assignment

Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERA

Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNORS:ALERE CONNECT, LLC;ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.);ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.);AND OTHERS;REEL/FRAME:036994/0192

Effective date: 20150618

AS Assignment

Owner name: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR

Free format text: ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT;REEL/FRAME:037115/0498

Effective date: 20151113

AS Assignment

Owner name: ALERE CONNECT, LLC, ARIZONA

Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258

Effective date: 20171003

Owner name: IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES,

Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258

Effective date: 20171003

Owner name: QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.), F

Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258

Effective date: 20171003

Owner name: STANDING STONE, LLC, CONNECTICUT

Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258

Effective date: 20171003

Owner name: INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA

Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258

Effective date: 20171003

Owner name: ESCREEN, INC., KANSAS

Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258

Effective date: 20171003

Owner name: ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHO

Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258

Effective date: 20171003

Owner name: ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA A

Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT;REEL/FRAME:044213/0258

Effective date: 20171003